文献速递脑血管病

双联抗血小板治疗对比阿替普酶对伴或不伴大血管闭塞的轻型卒中早期神经功能恶化的影响:ARAMIS试验预设事后分析

Dual Antiplatelet Versus Alteplase for Early Neurologic Deterioration in Minor Stroke With Versus Without Large Vessel Occlusion: Prespecified Post Hoc Analysis of the ARAMIS Trial.
PubMed 文献 · Stroke · 2024-10-10

ARAMIS试验预设事后分析纳入480例轻型非致残性急性缺血性卒中患者,分为大血管闭塞组(36例)和无大血管闭塞组(444例)。无大血管闭塞组中,双联抗血小板治疗(DAPT)较静脉阿替普酶显著降低24小时早期神经功能恶化(END)风险(校正风险差-4.8%,95%CI -6.9%至-2.6%,P<0.001)及出血事件(校正风险差-6.4%,95%CI -8.9%至-3.9%,P<0.001);大血管闭塞组两组END无显著差异(校正风险差2.3%,95%CI -17.6%至22.3%,P=0.82)。

要点

  • 无大血管闭塞的轻型非致残性卒中,DAPT较阿替普酶降低24小时END风险(校正风险差-4.8%,P<0.001)。
  • 无大血管闭塞组DAPT出血事件少于阿替普酶(校正风险差-6.4%,P<0.001)。
  • 大血管闭塞组DAPT与阿替普酶END无显著差异(校正风险差2.3%,P=0.82)。

核心结论

  • 在无大血管闭塞的轻型非致残性急性缺血性卒中患者中,DAPT在预防早期神经功能恶化方面可能优于静脉阿替普酶,且安全性更好。

研究设计与样本

  • ARAMIS试验(抗血小板对比rt-PA治疗急性轻型缺血性卒中)的预设事后分析。
  • 纳入ARAMIS试验按治疗分析集中有责任血管检查的患者,分为大血管闭塞组和无大血管闭塞组。
  • 每组再分为DAPT组和静脉阿替普酶组;共纳入480例患者,其中大血管闭塞组36例,无大血管闭塞组444例。

主要发现

  • 无大血管闭塞组中20例发生END;DAPT组END比例低于静脉阿替普酶组(校正风险差-4.8%,95%CI -6.9%至-2.6%,P<0.001)。
  • 大血管闭塞组中DAPT与静脉阿替普酶的END无显著差异(校正风险差2.3%,95%CI -17.6%至22.3%,P=0.82)。
  • 两组间交互作用边际显著(P=0.06)。
  • 无大血管闭塞组中DAPT组出血事件比例低于静脉阿替普酶组(校正风险差-6.4%,95%CI -8.9%至-3.9%,P<0.001)。
  • 其他安全性结局在两种治疗间相似。

关键数值与推荐

  • 主要结局为24小时END,定义为美国国立卫生研究院卒中量表评分较基线增加≥4分。
  • 安全性结局为研究期间的症状性颅内出血和出血事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiplatelet therapy (DAPT) was noninferior to alteplase in minor nondisabling strokes in the ARAMIS trial (Antiplatelet Versus R-tPA for Acute Mild Ischemic Stroke); however, early neurological deterioration (END) associated with vessel stenosis may benefit from DAPT. We investigated whether the efficacy of DAPT was greater than alteplase in minor strokes with no large vessel occlusion (LVO). METHODS: This study was a prespecified post hoc analysis of the ARAMIS trial and included patients with responsible vessel examination in the as-treated analysis set of the ARAMIS trial who were divided into LVO group and non-LVO group. In each group, patients were further classified into DAPT and intravenous alteplase treatments. Primary outcome was END at 24 hours defined as more than or equal to 4-point National Institutes of Health Stroke Scale score increase compared with baseline, and safety outcomes were symptomatic intracerebral hemorrhage and bleeding events during study. The primary analysis was estimated with a risk difference calculated by a generalized linear model including adjusted different baseline characteristics between treatments. RESULTS: Of 723 patients from the ARAMIS trial, 480 patients were included: 36 were categorized into LVO group and 444 into non-LVO group, of whom 20 patients had END. Compared with intravenous alteplase, a lower proportion of END was found after DAPT treatment in the non-LVO group (adjusted risk difference, -4.8% [95% CI, -6.9% to -2.6%]; P<0.001), but not in the LVO group (adjusted risk difference, 2.3% [95% CI, -17.6% to 22.3%]; P=0.82). The interaction was marginally significant between groups (P=0.06). In the non-LVO group, a lower proportion of bleeding events was found after DAPT treatment than intravenous alteplase (adjusted risk difference, -6.4% [95% CI, -8.9% to -3.9%]; P<0.001). Other safety outcomes were similar between the 2 treatments. CONCLUSIONS: Among minor nondisabling acute ischemic stroke without LVO, DAPT may be superior to intravenous alteplase regarding preventing END with a better safety profile. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03661411.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Cui Y, He C, Li ZA, et al. Dual Antiplatelet Versus Alteplase for Early Neurologic Deterioration in Minor Stroke With Versus Without Large Vessel Occlusion: Prespecified Post Hoc Analysis of the ARAMIS Trial. Stroke. 2024. PMID: 39387110. doi:10.1161/STROKEAHA.124.048248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。